Witryna1 lip 2024 · Abstract. Background Platinum chemotherapy (carboplatin or cisplatin) + etoposide is the current 1L standard of care treatment (tx) for ES-SCLC. Despite high response rates on this regimen, patient (pt) outcomes remain poor. IMpower133 is a Ph1/3, double-blind, randomized, placebo (PBO)-controlled trial that is evaluating the … Witryna6 lip 2024 · IMpower133研究是一项全球、随机、安慰剂对照的双盲研究,纳入403例初治广泛期SCLC患者。 所有患者接受4个周期的EC化疗,并随机分配接受联 …
【H星璀璨 1年陪伴】胡成平教授:免疫治疗时代斯鲁利单抗脱颖 …
Witryna31 sty 2024 · January 31, 2024 - The latest data from the IMpower133 trial shows that maintenance therapy with atezolizumab plus carboplatin and etoposide improves overall survival and progression-free... bitva u thermopyl 1962 online
ESMO Congress OncologyPRO
Witryna25 gru 2024 · 在IMpower133这个案例中,预先设置的分析时间和中止边界如下表所示,计划在发生240个和306个死亡事件时分别对OS进行期中分析和最终分析,利用R软件包(Idbounds)可以算出α值依次为0.0193和0.0257。 有意思的是,根据PFS是否显著,还可能涉及α回收的问题。 ... Witryna• IMpower133 demonstrated significant improvement in efficacy and tolerable safety with the addition of atezolizumab to chemotherapy (carboplatin and etoposide) and yielded statistically significant improvement in the ITT population Witryna11 kwi 2024 · Introduction. Approximately 15% of lung cancer cases are small-cell lung cancer (SCLC), which has a poor prognosis ().Platinum-based chemotherapy has been the standard first-line treatment for both limited-stage (LS) and extensive-stage (ES) disease since the 1980s, with an objective response rate (ORR) of about 65% and a … datchet weather forecast